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Interest in our laboratory in the inositol lipids derives from the presence of 
relatively high amounts of phosphatidylinositol phosphate (PhIP) and phos- 
phatidylinositol diphosphate (PhIPP) in excitable tissue. It was with this rela- 
tionship in mind that we embarked on a study of biosynthetic pathways of 
inositol lipids several years ago. 
A first step in the elucidation of biosynthetic pathways of phospholipids 
goes back to 1953, when Kornberg and Pricerl showed that a liver microsomal 
fraction catalyzed the acylation of glycerol-3-phosphate (G-3-P, L-a-glycero- 
phosphate) to diacyl-G-3-P (phosphatidate) , a lipid that was not previously 
known to be a biosynthetic intermediate substance. Subsequent studies indicated 
that phosphorylcholine was a precursor in the synthesis of phosphatidylch~line.~~~ 
Kennedy and Weiss, in 1955, found that ATP stimulated the incorporation of 
phosphorylcholine into lipid.4 An important step forward was taken when they 
learned that the stimulation by ATP was due to the presence of trace amounts 
of cytidine nucleotide.5 From this experiment evolved the role of CDP-choline 
and CDP-ethanolamine in phospholipid synthesis. A DPNH-linked dehydro- 
genase was found that reduced DHAP produced in glycolysis to G-3-P,6 which, 
in turn, could be acylated by the microsomal enzyme1 and fatty acyl-CoA to 
phosphatidate. Phosphatidate phosphohydrolasei was shown to cleave phos- 
phatidate to P, and l,Zdiglyceride, which then reacted with CDP-choline or 
CDP-ethanolamine to yield phosphatidylcholine and phosphatidylethanolamine, 
respectively. A pathway for phospholipid synthesis was thus proposed, begin- 
ning with the reduction of DHAP to G-3-P, acylation to phosphatidate, de- 
phosphorylation to diglyceride, and, finally, to yield phosphatidylcholine or 
phosphatidylethanolamine by reaction with the appropriate cytidine diphosphate 
derivative.s 
By analogy, we began to look for a similar system that would synthesize 
phosphatidylinositol (PhI). We looked in vain for an inositol kinase and for 
the presence of CDP-inositol, using inositol labeled with tritium by the Wilzbach 
technique or by reduction of scyllo-inosose.9 Although there was no evidence 
for inositol phosphate or CDP-inositol formation, we observed that cytidine 
nucleotides did significantly stimulate inositol incorporation into lipid in incu- 
bations with particulate fractions from kidney.1° When inositol was omitted, 
radioactivity from labeled CMP accumulated, as a function of time, into a 
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lipid phase.ll This observation, as well as related findings, led us to postulate 
the formation of a liponucleotide, CDP-diglyceride, and its subsequent cleavage 
by inositol to PhI and CMP. A clue to this pathway was present in the ex- 
periments of Dawson” and of Hokin and Hokin.13 They showed that the 
specific activity of phosphatidate and PhI were higher following incubation 
with “Pi than were other phospholipids. In the CDP-diglyceride pathway, 
phosphorus in phosphatidate enters the phospholipid, while in the diglyceride 
pathway, it does not. The role of CDP-diglyceride was substantiated by the 
studies of Paulus and Kennedy,14 who synthesized CDP-dipalmitin via dicyclo- 
hexylcarbodiimide. They proposed that the liponucleotide was formed by the 
action of a CTP :phosphatidate transferase: 
(1) 
The reaction was not unequivocally proven. For example, it had been 
shown that CTP reacted with G-3-P in bacterial systems to yield CDP-glycer01.1~ 
One might visualize that CDP-glycerol is acylated to form CDP-diglyceride. 
That CTP:phosphatidate transferase was in fact the reaction by which CDP- 
diglyceride forms was demonstrated much later in liver16 and in chicken brain.17 
In each instance, it was possible to demonstrate dependency on exogenously 
added phosphatidate for the formation of CDP-diglyceride. Although enzyme 
activity appears to be primarily in the mitochondria1 fraction in chick brain, 
it is most active in the microsomal fraction of guinea pig liver. 
The subsequent formation of phosphatidylinositol via CDP-diglyceride :inosi- 
to1 transferase: 
CTP + phosphatidate (PhA) * CDP-diglyceride + PP, 
CDP-diglyceride -t myo-inositol PhI + CMP (2) 
has been studied extensively in kidney,“ liver,14 and brain.ls-?O An improved 
method for the chemical synthesis of CDP-diglyceride was developed in our 
laboratory with use of CMP-morpholidate as an intermediate.z1 This substance 
is commercially available (Calbiochem) . For studies on CDP-dig1yceride:inosi- 
to1 transferase in guinea pig brain, a variety of CDP-diglycerides including 
C,,, C,,, C,, and C,, were synthesized.21 The products were separated by 
solvent distribution and silica gel column chromatography. The purity was 
checked by chromatography on formylated paper by which the various CDP- 
diglycerides were readily separated from their analogous phosphatidates. The 
CDP-diglyceride: inositol transferase was assayed by a spectrophotometric 
method based on the inositol-dependent release of CMP.14v17,20 While liver 
homogenates had the highest total activity, heart, lung, and spleen had the 
highest specific activities, and brain homogenate had a relatively high activity 
and a low endogenous (-inositol) rate.”O Upon fractionation of brain, the 
highest specific activity was in the 76,000 x g (crude microsomal) fraction. The 
presence of bovine serum albumin during incubation was found to be necessary 
for demonstration of full activity. Prottey and Hawthorne22 have also reported 
a similar effect with an enzyme preparation from kidney. Subfractionation 
according to a method of DeRobertis and co-workersZ3 revealed that the highest 
specific activity remained in the microsomal fraction, with rather uniform spe- 
cific activity in fractions B-E (“nerve endings” and “mitochondria”). 
Using the brain microsomal preparation, we found that the maximal rate 
with CDP-didecanoin was about six times higher than with CDP-dipalmitin. 
The short-chain derivative was therefore used for subsequent studies. In ex- 
periments with labeled inositol, stoichiometry of the transferase reaction was 
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demonstrated and the product was identified as PhI. One-half of the added 
CDP-DL-didecanoin reacted as expected, since only the D-a,/3-isomer (corre- 
sponding to G-3-P) should be active.20 CMP was identified as a product by 
electrophoresis at pH 1.5.24 The K, for inositol was 1 . 5 ~  l P 3 M  and for the 
active isomer of CDP-didecanoin, 8.2 x lP5M.20 
With CDP-didecanoin as the lipid acceptor, various cyclitols were examined 
as substrates. All nine isomers of hexahydroxycyclohexane were examined, but 
only rnyo-inositol was active. Cis-, scyllo- and epi-inositol were slightly in- 
hibitory. Mytilitol and isomytilitol25 were not available, but 2-0-C-methylene 
myo-inositoP was tested and found inactive as a substrate, as was the 2-C-OH- 
methyl derivative. None of the rnyo-inositol monophosphates served as sub- 
strates.20 
Galactinol ( 1-0-a,~-galactopyranosyl-2-3-rnyo-inositol) 27 was a noncom- 
petitive inhibitor of the reaction with 50% inhibition when added at equimolar 
concentrations with inositol. Two chromatographically purified inososes ap- 
peared to react with CDP-diglyceride in the presence of the guinea pig brain 
microsomal preparation.21 Similar results had been previously reported for 
chick l i ~ e r . 1 ~  Since we were using a spectrophotometric method at 280 mp, a 
question arose concerning the possible contribution to UV absorption from an 
enediol that could form during incubation from the added inososes. Experi- 
ments with inososes incubated with brain preparations in the absence of CDP- 
diglyceride gave variable results. In order to verify the formation of phos- 
phatidylinososes in brain, the lipid products from incubations with epi- or 
scyllo-inosose were reduced with NaB3H4. In each instance, a radioactive 
product could be demonstrated that chromatographed near PhI on formylated 
paper. However, the yields were only 1421% of that expected on the basis 
of CMP This might reflect instability of the phosphatidylinosose 
formed. The use of NaB3H4 should be of general applicability in the deter- 
mination of putative ketolipids. 
In other studies, we have investigated the further metabolism of PhI. In vitro 
s t ~ d i e s * ~ ~ ~ ~ J ~  have suggested the subsequent phosphorylation of brain PhI to 
PhIP and PhIPP. Colodzin and Kennedy3I reported a PhI kinase in brain. 
This enzyme and PhIP kinase have been studied in brain.S2*s3 Active phospha- 
tases are also present34p35J5 and may account for the rapid loss of PhIP from 
brain following death.36.37 
Evidence has accumulated that trace amounts of PhIP are present not only 
in nerve, but in all animal tissues e~amined .~~-~O Mitochondria incubated for 
short periods of time with 32P1 accumulate radioactivity in the phosphomono- 
ester position of PhIP.41 Using a similar system and Y - ~ ~ P - A T P  or 32Pi as 
precursors, we were able to show that three lipids are selectively labeled: PhIP, 
phosphatidate, and a new lipid, described Atractyloside blocks 3zP, -P 
PhIP, but not 32P1+AT3?P, or AT32P+Ph132P. This result suggests that 
there is an ATP-mediated PhI kinase and that the PhIP labeling system is not 
available to intramitochondrial ATP.42*43 
The novel lipid labeled under these conditions has been identified as 
acyldihydroxyacetone phosphate (acyl-DHAP) .44 The labeling by 32P, is appar- 
ently the result of the combined action of an acyl-DHA kinase and an acyl- 
DHAP phosphatase. The biosynthesis of acyl-DHAP was investigated and found 
to be catalyzed by a mitochondria1 preparation in the presence of acyl-CoA. 
Relatively high rates were found for palmitoyl- and ~ tearoyl -CoA,~~ compared 
with oleoyl-CoA. This is of interest, since it is known that the acylation of 
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G-3-P via the Kornberg-Pricer enzyme does not permit sufficient specificity for 
positions 1 or 2 of  phospholipid^*^,*^ to account for differences found between 
the two positions on analysis of phospholipids. It seemed possible that acyl- 
DHAP might constitute part of an alternative pathway that could permit this 
specificity. This proposal is given credence by our subsequent finding that 
mitochondria catalyze the TPNH-dependent reduction of acyl-DHAP to lyso- 
ph~spha t ida t e .~~  The product is I-acyl-G-3-P, as demonstrated by deacylation 
and oxidation of the glycerophosphate formed with the DPN-dependent en- 
~y rne .~*  Acylation of this lysophosphatidate to phosphatidate is rapidly cata- 
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FIGURE 1. Scheme of known pathways for the formation of inositol lipids. Dihy- 
droxyacetone phosphate arises from glucose via glycolysis or the oxidative shunt path- 
way. It can be acylated and reduced via mitochondria1 enzymes to lysophosphatidate 
and further acylated to phosphatidate. The previously known mechanism for phos- 
phatidate synthesis involved reduction to glycerophosphate via a cytoplasmic enzyme 
and two subsequent acylations. Phosphatidate may be cleaved to form diglyceride 
and be subsequently converted into phosphatidyl choline or phosphatidyl ethanol- 
amine. For inositol lipid formation, phosphatidate reacts with CTP to form CDP- 
diglyceride and pyrophosphate. CDP-diglyceride is then cleaved in the presence of 
myo-inositol to form CMP and phosphatidyl inositol. Di- and triphosphoinositide 
are produced by the action of kinases. 
Iyzed by both mitochondria1 and microsomal fractions of guinea pig liver, as 
has previously been reported when ~~-1ysophosphat ida te~~ or L-lysophospha- 
tidate ( 1 - a c ~ l - G - 3 - P ) ~ ~  is used as a substrate. Specificity of chain length and 
degree of saturation of the fatty acid for the second acylation is, in our hands, 
dependent on the concentration of 1-acyl-G-3-P and fatty acyl-CoA. 
The importance of this new pathway is at present not known. The levels of 
activity present in liver are comparable to or greater than that found for the 
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Kornberg-Pricer system. Since G-3-P is not an intermediate in the new pathway, 
the role of the acyl-DHAP pathway must be investigated under conditions such 
as hyperthyroidism or fasting, in which G-3-P dehydrogenase is known to be 
altered.51 
The known reactions in the biosynthesis of phosphatidylinositol are sum- 
marized in FIGURE 1. 
Summary 
Phosphatidylinositol is synthesized by the following reactions: 
CTP + phosphatidate ( PhA) CDP-diglyceride + PP, (1) 
CDP-diglyceride + myo-inositol PhI + CMP (2) 
Guinea pig brain microsomes show specificity for myo-inositol, although 
inososes also appear to act as substrates. Synthetic CDP-DL-didecanoin has 
been used as a model substrate. Galactinol ( l-O-a,~-galactopyranosyl-2,3-myo- 
inositol) is an effective inhibitor of the reaction. 
The subsequent phosphorylation of PhI to PhIP by ATP has been studied 
in guinea pig liver mitochondria with Y-~~P-ATP.  Evidence is obtained that 
intramitochondrial ATP is in a compartment separate from the PhIP labeling 
system. In the course of these studies, we have gained new information on 
the biosynthesis of PhA as well. A novel pathway is proposed for the biosyn- 
thesis of PhA via a new lipid, acyldihydroxyacetone phosphate. The transfer 
of fatty acid from CoA to dihydroxyacetone phosphate is catalyzed by a mito- 
chondrial preparation, which reduces the product to lysophosphatidate in the 
presence of TPNH. Thus glycerophosphate may not be an obligatory inter- 
mediate in the formation of glycerolipids. 
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